The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Antihemophilic Factor Drug Market Research Report 2025
Synopsis
Antihemophilic Factor Drug is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is also used in these patients before surgery to prevent bleeding.
The global Antihemophilic Factor Drug market was valued at US$ 541 million in 2023 and is anticipated to reach US$ 796 million by 2030, witnessing a CAGR of 6.1% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Antihemophilic Factor Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antihemophilic Factor Drug.
Report Scope
The Antihemophilic Factor Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antihemophilic Factor Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antihemophilic Factor Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer
Takeda
Novo Nordisk
Pfizer
Grifols
CSL Behring
Sanofi
Cigna
Octapharma
GC Pharma
Hualan Biological Engineering
Shanghai RAAS blood products
Segment by Type
250 IU
500 IU
1000 IU
1500 IU
2000 IU
3000 IU
4000 IU
Other potencies
Segment by Application
Adult
Pediatric
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Antihemophilic Factor Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Antihemophilic Factor Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Antihemophilic Factor Drug is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is also used in these patients before surgery to prevent bleeding.
The global Antihemophilic Factor Drug market was valued at US$ 541 million in 2023 and is anticipated to reach US$ 796 million by 2030, witnessing a CAGR of 6.1% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Antihemophilic Factor Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antihemophilic Factor Drug.
Report Scope
The Antihemophilic Factor Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antihemophilic Factor Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antihemophilic Factor Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer
Takeda
Novo Nordisk
Pfizer
Grifols
CSL Behring
Sanofi
Cigna
Octapharma
GC Pharma
Hualan Biological Engineering
Shanghai RAAS blood products
Segment by Type
250 IU
500 IU
1000 IU
1500 IU
2000 IU
3000 IU
4000 IU
Other potencies
Segment by Application
Adult
Pediatric
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Antihemophilic Factor Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Antihemophilic Factor Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Antihemophilic Factor Drug Market Overview
1.1 Product Overview and Scope of Antihemophilic Factor Drug
1.2 Antihemophilic Factor Drug Segment by Type
1.2.1 Global Antihemophilic Factor Drug Market Value Comparison by Type (2024-2030)
1.2.2 250 IU
1.2.3 500 IU
1.2.4 1000 IU
1.2.5 1500 IU
1.2.6 2000 IU
1.2.7 3000 IU
1.2.8 4000 IU
1.2.9 Other potencies
1.3 Antihemophilic Factor Drug Segment by Application
1.3.1 Global Antihemophilic Factor Drug Market Value by Application: (2024-2030)
1.3.2 Adult
1.3.3 Pediatric
1.4 Global Antihemophilic Factor Drug Market Size Estimates and Forecasts
1.4.1 Global Antihemophilic Factor Drug Revenue 2019-2030
1.4.2 Global Antihemophilic Factor Drug Sales 2019-2030
1.4.3 Global Antihemophilic Factor Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Antihemophilic Factor Drug Market Competition by Manufacturers
2.1 Global Antihemophilic Factor Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Antihemophilic Factor Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Antihemophilic Factor Drug Average Price by Manufacturers (2019-2024)
2.4 Global Antihemophilic Factor Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Antihemophilic Factor Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antihemophilic Factor Drug, Product Type & Application
2.7 Antihemophilic Factor Drug Market Competitive Situation and Trends
2.7.1 Antihemophilic Factor Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Antihemophilic Factor Drug Players Market Share by Revenue
2.7.3 Global Antihemophilic Factor Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Antihemophilic Factor Drug Retrospective Market Scenario by Region
3.1 Global Antihemophilic Factor Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Antihemophilic Factor Drug Global Antihemophilic Factor Drug Sales by Region: 2019-2030
3.2.1 Global Antihemophilic Factor Drug Sales by Region: 2019-2024
3.2.2 Global Antihemophilic Factor Drug Sales by Region: 2025-2030
3.3 Global Antihemophilic Factor Drug Global Antihemophilic Factor Drug Revenue by Region: 2019-2030
3.3.1 Global Antihemophilic Factor Drug Revenue by Region: 2019-2024
3.3.2 Global Antihemophilic Factor Drug Revenue by Region: 2025-2030
3.4 North America Antihemophilic Factor Drug Market Facts & Figures by Country
3.4.1 North America Antihemophilic Factor Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Antihemophilic Factor Drug Sales by Country (2019-2030)
3.4.3 North America Antihemophilic Factor Drug Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Antihemophilic Factor Drug Market Facts & Figures by Country
3.5.1 Europe Antihemophilic Factor Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Antihemophilic Factor Drug Sales by Country (2019-2030)
3.5.3 Europe Antihemophilic Factor Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antihemophilic Factor Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Antihemophilic Factor Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Antihemophilic Factor Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Antihemophilic Factor Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Antihemophilic Factor Drug Market Facts & Figures by Country
3.7.1 Latin America Antihemophilic Factor Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Antihemophilic Factor Drug Sales by Country (2019-2030)
3.7.3 Latin America Antihemophilic Factor Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Antihemophilic Factor Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Antihemophilic Factor Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Antihemophilic Factor Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Antihemophilic Factor Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antihemophilic Factor Drug Sales by Type (2019-2030)
4.1.1 Global Antihemophilic Factor Drug Sales by Type (2019-2024)
4.1.2 Global Antihemophilic Factor Drug Sales by Type (2025-2030)
4.1.3 Global Antihemophilic Factor Drug Sales Market Share by Type (2019-2030)
4.2 Global Antihemophilic Factor Drug Revenue by Type (2019-2030)
4.2.1 Global Antihemophilic Factor Drug Revenue by Type (2019-2024)
4.2.2 Global Antihemophilic Factor Drug Revenue by Type (2025-2030)
4.2.3 Global Antihemophilic Factor Drug Revenue Market Share by Type (2019-2030)
4.3 Global Antihemophilic Factor Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Antihemophilic Factor Drug Sales by Application (2019-2030)
5.1.1 Global Antihemophilic Factor Drug Sales by Application (2019-2024)
5.1.2 Global Antihemophilic Factor Drug Sales by Application (2025-2030)
5.1.3 Global Antihemophilic Factor Drug Sales Market Share by Application (2019-2030)
5.2 Global Antihemophilic Factor Drug Revenue by Application (2019-2030)
5.2.1 Global Antihemophilic Factor Drug Revenue by Application (2019-2024)
5.2.2 Global Antihemophilic Factor Drug Revenue by Application (2025-2030)
5.2.3 Global Antihemophilic Factor Drug Revenue Market Share by Application (2019-2030)
5.3 Global Antihemophilic Factor Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Corporation Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bayer Antihemophilic Factor Drug Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Takeda
6.2.1 Takeda Corporation Information
6.2.2 Takeda Description and Business Overview
6.2.3 Takeda Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Takeda Antihemophilic Factor Drug Product Portfolio
6.2.5 Takeda Recent Developments/Updates
6.3 Novo Nordisk
6.3.1 Novo Nordisk Corporation Information
6.3.2 Novo Nordisk Description and Business Overview
6.3.3 Novo Nordisk Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Novo Nordisk Antihemophilic Factor Drug Product Portfolio
6.3.5 Novo Nordisk Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer Antihemophilic Factor Drug Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Grifols
6.5.1 Grifols Corporation Information
6.5.2 Grifols Description and Business Overview
6.5.3 Grifols Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Grifols Antihemophilic Factor Drug Product Portfolio
6.5.5 Grifols Recent Developments/Updates
6.6 CSL Behring
6.6.1 CSL Behring Corporation Information
6.6.2 CSL Behring Description and Business Overview
6.6.3 CSL Behring Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 CSL Behring Antihemophilic Factor Drug Product Portfolio
6.6.5 CSL Behring Recent Developments/Updates
6.7 Sanofi
6.6.1 Sanofi Corporation Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sanofi Antihemophilic Factor Drug Product Portfolio
6.7.5 Sanofi Recent Developments/Updates
6.8 Cigna
6.8.1 Cigna Corporation Information
6.8.2 Cigna Description and Business Overview
6.8.3 Cigna Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Cigna Antihemophilic Factor Drug Product Portfolio
6.8.5 Cigna Recent Developments/Updates
6.9 Octapharma
6.9.1 Octapharma Corporation Information
6.9.2 Octapharma Description and Business Overview
6.9.3 Octapharma Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Octapharma Antihemophilic Factor Drug Product Portfolio
6.9.5 Octapharma Recent Developments/Updates
6.10 GC Pharma
6.10.1 GC Pharma Corporation Information
6.10.2 GC Pharma Description and Business Overview
6.10.3 GC Pharma Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
6.10.4 GC Pharma Antihemophilic Factor Drug Product Portfolio
6.10.5 GC Pharma Recent Developments/Updates
6.11 Hualan Biological Engineering
6.11.1 Hualan Biological Engineering Corporation Information
6.11.2 Hualan Biological Engineering Antihemophilic Factor Drug Description and Business Overview
6.11.3 Hualan Biological Engineering Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Hualan Biological Engineering Antihemophilic Factor Drug Product Portfolio
6.11.5 Hualan Biological Engineering Recent Developments/Updates
6.12 Shanghai RAAS blood products
6.12.1 Shanghai RAAS blood products Corporation Information
6.12.2 Shanghai RAAS blood products Antihemophilic Factor Drug Description and Business Overview
6.12.3 Shanghai RAAS blood products Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Shanghai RAAS blood products Antihemophilic Factor Drug Product Portfolio
6.12.5 Shanghai RAAS blood products Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antihemophilic Factor Drug Industry Chain Analysis
7.2 Antihemophilic Factor Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antihemophilic Factor Drug Production Mode & Process
7.4 Antihemophilic Factor Drug Sales and Marketing
7.4.1 Antihemophilic Factor Drug Sales Channels
7.4.2 Antihemophilic Factor Drug Distributors
7.5 Antihemophilic Factor Drug Customers
8 Antihemophilic Factor Drug Market Dynamics
8.1 Antihemophilic Factor Drug Industry Trends
8.2 Antihemophilic Factor Drug Market Drivers
8.3 Antihemophilic Factor Drug Market Challenges
8.4 Antihemophilic Factor Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
